Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    TScan Therapeutics Inc.

    NASDAQ: TCRX · Real-Time Price · USD
    1.80
    0.12 (7.14%)
    At close: Jun 06, 2025, 3:59 PM
    1.81
    0.28%
    After-hours: Jun 06, 2025, 05:04 PM EDT

    TScan Therapeutics Statistics

    Share Statistics

    TScan Therapeutics has 56.59M shares outstanding. The number of shares has increased by 7.05% in one year.

    Shares Outstanding

    n/a
    		 56.59M

    Shares Change (YoY)

    n/a
    		 7.05%

    Shares Change (QoQ)

    n/a
    		 6.03%

    Owned by Institutions (%)

    n/a
    		 34.99%

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 203

    FTD / Avg. Volume

    n/a
    		 0.03%

    Short Selling Information

    The latest short interest is 2.3M, so 4.07% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 2.3M

    Short % of Shares Out

    n/a
    		 4.07%

    Short % of Float

    n/a
    		 4.95%

    Short Ratio (days to cover)

    n/a
    		 8.89

    Valuation Ratios

    The PE ratio is -2.67 and the forward PE ratio is -1.5. TScan Therapeutics's PEG ratio is 0.17.

    PE Ratio

    n/a
    		 -2.67

    Forward PE

    n/a
    		 -1.5

    PS Ratio

    n/a
    		 120.9

    Forward PS

    n/a
    		 0.8

    PB Ratio

    n/a
    		 1.41

    P/FCF Ratio

    n/a
    		 -2.97

    PEG Ratio

    n/a
    		 0.17
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for TScan Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 8.14, with a Debt / Equity ratio of 0.4.

    Current Ratio

    n/a
    		 8.14

    Quick Ratio

    n/a
    		 8.14

    Debt / Equity

    n/a
    		 0.4

    Debt / EBITDA

    n/a
    		 -0.81

    Debt / FCF

    n/a
    		 -0.85

    Interest Coverage

    n/a
    		 -36.91

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $14,080

    Profits Per Employee

    n/a
    		 $-637,495

    Employee Count

    n/a
    		 200

    Asset Turnover

    n/a
    		 0.01

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -80.72% in the last 52 weeks. The beta is 0.97, so TScan Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.97

    52-Week Price Change

    n/a
    		 -80.72%

    50-Day Moving Average

    n/a
    		 1.4

    200-Day Moving Average

    n/a
    		 3.25

    Relative Strength Index (RSI)

    n/a
    		 61.27

    Average Volume (20 Days)

    n/a
    		 588,384

    Income Statement

    In the last 12 months, TScan Therapeutics had revenue of 2.82M and earned -127.5M in profits. Earnings per share was -1.14.

    Revenue

    n/a
    		 2.82M

    Gross Profit

    n/a
    		 2.82M

    Operating Income

    n/a
    		 -134.82M

    Net Income

    n/a
    		 -127.5M

    EBITDA

    n/a
    		 -119.74M

    EBIT

    n/a
    		 -123.85M

    Earnings Per Share (EPS)

    n/a
    		 -1.14
    Full Income Statement

    Balance Sheet

    The company has 178.69M in cash and 97.38M in debt, giving a net cash position of 81.31M.

    Cash & Cash Equivalents

    n/a
    		 178.69M

    Total Debt

    n/a
    		 97.38M

    Net Cash

    n/a
    		 81.31M

    Retained Earnings

    n/a
    		 -375.1M

    Total Assets

    n/a
    		 332.71M

    Working Capital

    n/a
    		 225.02M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -110.82M and capital expenditures -3.83M, giving a free cash flow of -114.65M.

    Operating Cash Flow

    n/a
    		 -110.82M

    Capital Expenditures

    n/a
    		 -3.83M

    Free Cash Flow

    n/a
    		 -114.65M

    FCF Per Share

    n/a
    		 -1.02
    Full Cash Flow Statement

    Margins

    Gross margin is 100%, with operating and profit margins of -4787.68% and -4527.66%.

    Gross Margin

    n/a
    		 100%

    Operating Margin

    n/a
    		 -4787.68%

    Pretax Margin

    n/a
    		 -4527.66%

    Profit Margin

    n/a
    		 -4527.66%

    EBITDA Margin

    n/a
    		 -4252.06%

    EBIT Margin

    n/a
    		 -4787.68%

    FCF Margin

    n/a
    		 -4071.27%

    Dividends & Yields

    TCRX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for TCRX is $10, which is 498.8% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $10

    Price Target Difference

    n/a
    		 498.8%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 5
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -1.79

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist